newsfilter
← Latest News
Business Wire·

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

Three top-line Phase 3 data read-outs for Rubraca expected in 2022, with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy Phase 1/2 LuMIERE study of targeted radiotherapy candidate FAP-2286 on